The London-based research firm Visiongain has recently published a new report detailing market analysis for cholesterol-lowering drugs for the next ten years. The report itself costs more than $3000 to buy, however, Visiongain have issued a press release containing highlights from the report, which tells us everything we need to know.
In 2017 the global cholesterol-lowering industry is worth $19.2 Billion and is forecast to grow 4.9% each year during the next five years. Which means that the industry will be worth $24.4 Billion in 2022.
This data flies in the face of the numerous media reports we have seen in recent years referring to statins as cheap, costing a few pennies. Those people supporting the mass use of statins have also tried to claim that the financial incentive to lie to people about statins and cholesterol no longer exists because statins are cheap and most statins are off-patent. Clearly, the financial incentive to keep this terrible mess going is very much still there.
Back in 2009, I estimated the global cholesterol-lowering industry to be worth around $29 Billion, including both drugs and the revenue food manufacturers receive by marketing cholesterol-lowering or "low in cholesterol" products.
The new market analysis includes a range of drugs in addition to statins including cholesterol absorption inhibitors, ion exchange resins, vibrates, PCSK9 Inhibitors, and others.
In the statins category, Crestor was leading in 2016, being associated with a market share of 26.7%.
The largest clinical trial done on Crestor is the JUPITER trial, which is full of controversy (see the excerpt from Statin Nation below) and the results of this trial have been questioned by other researchers.